Delivery Order SPE2DB24D6039-SPE2DB25FLEMR
- Not listed
- This is a delivery order awarded by the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The $2,769.28 firm fixed-price contract is for the delivery of Vimpat 200 mg tablets. It has an ultimate completion date of September 22, 2022. AmerisourceBergen holds a significant $999,999,999 Indefinite Delivery Contract (IDC) with the DLA Troop Support Medical, which serves as the primary vehicle for the company to...
- The Defense Logistics Agency awarded a $235,910 firm fixed price delivery order contract to Amerisourcebergen Drug Corporation to supply 56,100 tablets of the anti-seizure medication Vimpat. As the prime contractor, Amerisourcebergen will deliver the product to a facility in Conshohocken, Pennsylvania by September 5, 2023 under the terms of the contract. No subcontractors or set aside designations were specified. The Defense Logistics Agency manages the global supply chain for the United...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on August 20, 2025, for the supply of Vimpat 200 mg tablets in quantities of 60 units, with a firm fixed price ceiling value of $3,455.90. This delivery order represents a non-competitive, non-set-aside award and is scheduled for completion by August 21, 2025. The order will be fulfilled from the vendor's facility in Conshohocken, Pennsylvania. Vimpat is a prescription antiepileptic medication used in the...
- The Defense Logistics Agency awarded Amerisourcebergen Drug Corporation a firm fixed price delivery order valued at one thousand four hundred seventy-two dollars and fifty-four cents to provide Vimpat 100 mg tablets. Under the terms of the contract, Amerisourcebergen will deliver sixty tablets to a facility in Conshohocken, Pennsylvania, with performance required between September 11-12, 2023. As a leading provider of pharmaceuticals and healthcare solutions to the Department of Defense,...
- The Defense Logistics Agency Troop Support Medical awarded a $454,000 delivery order to Amerisourcebergen Drug Corporation for Vimpat 50 mg tablets. Under the terms of the firm fixed price contract, Amerisourcebergen will deliver 60,000 Vimpat tablets to a facility in Conshohocken, Pennsylvania between September 8-11, 2023. As a major provider of pharmaceuticals and medical supplies, Amerisourcebergen will fulfill this requirement to support the Defense Logistics Agency's mission of providing...
- This is a firm fixed-price delivery order awarded by the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a major pharmaceutical distributor. The contract, valued at $1,746.97, is for the supply of 60 tablets of Vimpat 200 mg, a medication used to treat epilepsy. The contract has an ultimate completion date of May 2, 2025. AmerisourceBergen Drug Corp is the prime contractor, and there is no set-aside designation, indicating open competition. The award is part of a larger Indefinite...
- The Defense Logistics Agency (DLA) awarded a delivery order valued at $2,495.07 to AmerisourceBergen Drug Corp for the supply of Vimpat 10 mg/ml solution in a 200 ml quantity. This non-set-aside, competitively awarded contract utilizes firm fixed pricing and was issued on July 25, 2025, with an ultimate completion date of July 28, 2025. The place of performance is AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. This delivery order represents a single transaction...
- This is a delivery order awarded by the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The contract, valued at $2,840.98, is for the supply of Vimpat 100 mg tablets to support military healthcare programs. It is a firm fixed-price contract with a period of performance through February 2024. The contract was not designated with a set-aside requirement, indicating open competition. AmerisourceBergen Drug Corp...
- This is a federal contract award from the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a major pharmaceutical distributor. The contract, valued at $1,493.45, is for the delivery of Vimpat 150 mg tablets. It is a firm fixed-price delivery order with an ultimate completion date of April 22, 2025. The contract is not set aside and is open to competition. AmerisourceBergen Drug Corp holds a significant Indefinite Delivery Contract (IDC) with the DLA Troop Support Medical, valued at...
- This federal contract award, valued at $1,229.93, was issued by the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The contract is for the delivery of Vimpat 150 mg tablets, a medication used to treat certain types of epilepsy. The contract is a Firm Fixed Price Delivery Order with an ultimate completion date of April 30, 2025. The contract is not set aside for any specific business category....
- SPE2DB24D6039Indefinite Delivery Contract
- SPE2DB24D6039-SPE2DB25FLEMRDelivery Order
The Defense Logistics Agency awarded a delivery order valued at $2,287.32 to AmerisourceBergen Drug Corp for 60 tablets of Vimpat 100 mg on August 26, 2025, with completion scheduled for August 27, 2025. This is a firm fixed price, competitively awarded contract with no set-aside designation. The work will be performed at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. This delivery order is issued under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical (SPE2DX), a comprehensive global pharmaceutical support vehicle valued at $999,999,999 and extending through December 2026. Vimpat is a neurological medication used for seizure management, consistent with AmerisourceBergen's extensive portfolio of pharmaceutical products and medical supplies supporting federal military and veteran healthcare systems. As a major pharmaceutical distributor, AmerisourceBergen serves as a critical vendor for the Defense Health Agency and other government healthcare customers, fulfilling orders across multiple therapeutic domains including specialty medications, brand-name and generic drugs, and medical devices. The company's primary IDC with DLA demonstrates its significant capability to meet federal procurement requirements through open competition and support military healthcare programs globally.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | Not listed | $2.3k | 8/26/25 |